Nevertheless, Zhou et al. illustrated that Siglec‐15 was associated with a better pathological response and more favorable survival in ESCC patients receiving neoadjuvant chemoradiotherapy, implying a beneficial element of Siglec‐15 role in the treatment of human cancer.33 Here, SIGLEC15 is linked to cancer.